| 2.23 0.03 (1.36%) | 07-10 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.76 | 1-year : | 3.09 |
| Resists | First : | 2.36 | Second : | 2.65 |
| Pivot price | 2.18  |
|||
| Supports | First : | 1.89 | Second : | 1.58 |
| MAs | MA(5) : | 2.31 |
MA(20) : | 2.17 |
| MA(100) : | 2.41 |
MA(250) : | 3.13 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 41.7 |
D(3) : | 53.6 |
| RSI | RSI(14): 47.9 |
|||
| 52-week | High : | 4.76 | Low : | 1.65 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CLVT ] has closed below upper band by 44.1%. Bollinger Bands are 15.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.37 - 2.38 | 2.38 - 2.39 |
| Low: | 2.18 - 2.2 | 2.2 - 2.21 |
| Close: | 2.21 - 2.23 | 2.23 - 2.25 |
Clarivate Plc operates as a prominent information services and analytics firm, furnishing structured data and insights. Its core mission is to facilitate the discovery, safeguard the intellectual property, and enable the commercialization of scientific research, innovations, and established brands. The company's portfolio includes the extensive Web of Science suite, a collection of essential tools such as Web of Science, InCites, Journal Citation Reports, EndNote, ScholarOne, Converis, Publons, and Kopernio. These are designed to support organizations throughout the entire research lifecycle, from initial planning and funding to execution and utilization. Within the Life Sciences domain, Clarivate provides specialized products like Cortellis and Newport Integrity. These platforms cater to pharmaceutical and biotechnology companies, empowering their research endeavors, supplying vital market intelligence, and facilitating competitive monitoring during the development and launch phases of novel drugs. Its Derwent product line, comprising Derwent Innovation, Techstreet, and IP Professional Services, is dedicated to intellectual property management. These tools enable customers to evaluate the originality of potential products, establish their freedom to operate within design parameters, secure patent protection, analyze the competitive technological landscape, and ensure adherence to essential industry standards. Complementing these, CompuMark delivers trademark screening, search, and monitoring solutions vital for businesses and legal firms. Meanwhile, MarkMonitor empowers enterprises to establish, manage, optimize, and fortify their digital presence. Clarivate's diverse clientele spans government agencies, academic institutions, life science enterprises, and research and development corporations worldwide, with operations across the Americas, Middle East, Africa, Europe, and Asia Pacific regions. The company, initially known as Clarivate Analytics Plc, rebranded to Clarivate Plc in May 2020. It maintains its headquarters in London, United Kingdom.
Sun, 12 Jul 2026
Clarivate (CLVT) to Sell Life Sciences & Healthcare Business to Altaris For $600 Million - Yahoo Finance
Sun, 12 Jul 2026
Clarivate jumps 16% on $600M sale of life sciences segment - MSN
Fri, 10 Jul 2026
Clarivate to Report Second Quarter 2026 Results on July 29, 2026 - Finviz
Fri, 10 Jul 2026
Clarivate schedules July 29 webcast on Q2 2026 results - Stock Titan
Mon, 06 Jul 2026
Clarivate (NYSE: CLVT) to divest Life Sciences & Healthcare arm for $600M - Stock Titan
Mon, 06 Jul 2026
Clarivate (CLVT) M&A announcement Summary - Quartr
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Technology
|
|
|
Industry:
Information Technology Services
|
|
| Shares Out | 639 (M) |
| Shares Float | 468 (M) |
| Held by Insiders | 18.3 (%) |
| Held by Institutions | 91.5 (%) |
| Shares Short | 52,480 (K) |
| Shares Short P.Month | 56,260 (K) |
| EPS | -0.21 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.48 |
| Profit Margin | -5.7 % |
| Operating Margin | 5 % |
| Return on Assets (ttm) | 0.9 % |
| Return on Equity (ttm) | -2.8 % |
| Qtrly Rev. Growth | -1.4 % |
| Gross Profit (p.s.) | 2.54 |
| Sales Per Share | 3.83 |
| EBITDA (p.s.) | 1.45 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 592 (M) |
| Levered Free Cash Flow | 473 (M) |
| PE Ratio | -10.62 |
| PEG Ratio | 0.1 |
| Price to Book value | 0.29 |
| Price to Sales | 0.58 |
| Price to Cash Flow | 2.4 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|